Financials data is unavailable for this security.
View more
Year on year Zhejiang Shapuaisi Pharmaceutical Co Ltd had net income fall -43.23% from 44.75m to 25.41m despite a 17.37% increase in revenues from 549.54m to 644.97m. An increase in the selling, general and administrative costs as a percentage of sales from 34.71% to 42.88% was a component in the falling net income despite rising revenues.
Gross margin | 51.90% |
---|---|
Net profit margin | -13.49% |
Operating margin | -12.06% |
Return on assets | -3.48% |
---|---|
Return on equity | -4.20% |
Return on investment | -4.00% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Zhejiang Shapuaisi Pharmaceutical Co Ltd fell by 169.39m. Cash Flow from Financing totalled 135.01m or 20.93% of revenues. In addition the company generated 41.49m in cash from operations while cash used for investing totalled 345.89m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.46 |
---|---|
Tangible book value per share | 2.97 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.08 |
---|---|
Quick ratio | 0.8094 |
Total debt/total equity | 0.1481 |
---|---|
Total debt/total capital | 0.1284 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -43.24% and -51.29%, respectively.
Div yield(5 year avg) | 0.14% |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | -- |
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -185.39 |
More ▼